Tim Avis

5.3k total citations
8 papers, 55 citations indexed

About

Tim Avis is a scholar working on Molecular Biology, Oncology and Infectious Diseases. According to data from OpenAlex, Tim Avis has authored 8 papers receiving a total of 55 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Infectious Diseases. Recurrent topics in Tim Avis's work include Clostridium difficile and Clostridium perfringens research (3 papers), PARP inhibition in cancer therapy (3 papers) and Viral gastroenteritis research and epidemiology (2 papers). Tim Avis is often cited by papers focused on Clostridium difficile and Clostridium perfringens research (3 papers), PARP inhibition in cancer therapy (3 papers) and Viral gastroenteritis research and epidemiology (2 papers). Tim Avis collaborates with scholars based in United Kingdom and United States. Tim Avis's co-authors include Clive Mason, Nawaz Khan, David J. Powell, Francis X. Wilson, Elena B. M. Breidenstein, Nabeetha Nagalingam, Thomas P. Duffy, James Carmichael, Aisling O'Shaughnessy and Kathleen Gajewski and has published in prestigious journals such as Cancer Research, Antimicrobial Agents and Chemotherapy and Drug Discovery Today.

In The Last Decade

Tim Avis

7 papers receiving 52 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tim Avis United Kingdom	5	28	16	11	9	7	8	55
Rodion Gordzevich Canada	2	15 0.5×	39 2.4×	5 0.5×	4 0.4×	3 0.4×	4	53
Amanda N. Seddon United States	4	13 0.5×	13 0.8×	10 0.9×	3 0.3×	11 1.6×	10	54
Mohammed Elshaer Egypt	4	18 0.6×	9 0.6×	5 0.5×	6 0.7×	14 2.0×	16	58
Haley L. Zubyk Canada	3	24 0.9×	48 3.0×	4 0.4×	6 0.7×	25 3.6×	5	80
Kemal İnecik Switzerland	2	21 0.8×	16 1.0×		6 0.7×	5 0.7×	2	43
Souad Kartti Morocco	4	24 0.9×	6 0.4×	5 0.5×	2 0.2×	6 0.9×	13	39
Felicitas Elena Calvo Spain	3	11 0.4×	27 1.7×	3 0.3×	9 1.0×	3 0.4×	4	34
Stephanie Gresham United Kingdom	3	32 1.1×	6 0.4×	5 0.5×	1 0.1×	29 4.1×	3	61
David Lähnemann Germany	4	18 0.6×	16 1.0×	3 0.3×	4 0.4×	3 0.4×	6	49
Upasana Das Adhikari United States	4	41 1.5×	2 0.1×	17 1.5×	4 0.4×	9 1.3×	6	112

Countries citing papers authored by Tim Avis

Since Specialization

Citations

This map shows the geographic impact of Tim Avis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Avis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Avis more than expected).

Fields of papers citing papers by Tim Avis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Avis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Avis. The network helps show where Tim Avis may publish in the future.

Co-authorship network of co-authors of Tim Avis

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Avis. A scholar is included among the top collaborators of Tim Avis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Avis. Tim Avis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Mason, Clive, Tim Avis, Chenlin Hu, et al.. (2023). The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic. Antimicrobial Agents and Chemotherapy. 67(5). e0156322–e0156322. 5 indexed citations

Breidenstein, Elena B. M., et al.. (2023). SMT-738: a novel small-molecule inhibitor of bacterial lipoprotein transport targeting Enterobacteriaceae. Antimicrobial Agents and Chemotherapy. 68(1). e0069523–e0069523. 10 indexed citations

Avis, Tim, Francis X. Wilson, Nawaz Khan, Clive Mason, & David J. Powell. (2021). Targeted microbiome-sparing antibiotics. Drug Discovery Today. 26(9). 2198–2203. 28 indexed citations

Mason, Clive, Tim Avis, D.R. Powell, et al.. (2021). 1052. Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of Clostridioides difficile. Open Forum Infectious Diseases. 8(Supplement_1). S617–S617.

Avis, Tim, Stephan Beisken, Elena B. M. Breidenstein, et al.. (2020). High-density transposon libraries utilising outward-oriented promoters identify mechanisms of action and resistance to antimicrobials. FEMS Microbiology Letters. 367(22). 5 indexed citations

Dry, Jonathan R., Alan Lau, Charlotte Knights, et al.. (2010). Abstract 3497: Identifying pre-clinical predictive biomarkers for the PARP inhibitor olaparib. Cancer Research. 70(8_Supplement). 3497–3497. 1 indexed citations

Knights, Charlotte, Lucy C. Riches, Alan Lau, et al.. (2009). Abstract #5494: Pre-clinical evaluation of single-agent activity of the PARP inhibitor olaparib (AZD2281) in homologous recombination deficient triple-negative breast cancer. Cancer Research. 69. 5494–5494. 1 indexed citations

Knights, Charlotte, Christine M. Chresta, Lucy C. Riches, et al.. (2009). Abstract A114: Preclinical evaluation of the PARP inhibitor olaparib in homologous recombination deficient (HRD) MRE11 mutant microsatellite instable (MSI) colorectal cancer. Molecular Cancer Therapeutics. 8(12_Supplement). A114–A114. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact